

Global Cell and Gene Therapy Business and Investment Opportunities - Analysis and Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update

Market Report | 2023-02-22 | 1350 pages | BioIntel360

AVAILABLE LICENSES:

- Single User Price \$8900.00
- Multi User Price \$9900.00
- Enterprise User Price \$11900.00

Report description:

Insights and data in the report have been segmented under the following six modules:

Module 1: Global Cell and Gene Therapy Funding and Investments Outlook

This module provides insights and data related to cell and gene therapy partnerships and investment (research and development, mergers and acquisitions, product development, commercialization, licensing, and manufacturing) and allows a peek into the futuristic trends of cell and gene therapy technology investment area.

Module 2: Global Cell and Gene Therapy Clinical Trial Data Assessment

This module evaluates the data available from clinical trials conducted in this sector, representing a bird's eye view of emerging market dynamics and risks in the cell and gene therapy sector.

Module 3: Global Cell and Gene Therapy Patent Data Analysis

This module presents an exhaustive study of cell and gene therapy patent analytics at various levels, including strategic research planning as well as analyzing their potential applications.

Module 4: Competitive Landscape

This module provides detailed information along with a scoring matrix of key companies related to the cell and gene therapy industry, including their historical performance and the latest developments.

Module 5: Global Cell and Gene Therapy Market Size and Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

This module provides projections on the market's development during the years 2018-2027 after the profound evaluation of market dynamics at the deeper segmentation level. This report also provides an in-depth, data-centric analysis of the global cell and gene therapy market at regional and country levels:

Cell & Gene Therapy Market Size by Different Therapy Segment, 2018-2027

- Cell and Gene Modified Cell Therapies
- Gene Therapy and Genome Therapy
- DNA & RNA Therapeutics

Cell & Gene Therapy Market Size by Purpose of Manufacturing

- Commercial
- Clinical

Cell & Gene Therapy Market Size by Product

- Abecma
- Amondys
- Breyanzi
- Carvykti
- Givlaari
- Kimmtrak
- Kymriah
- Leqvio
- Luxturna
- Onpattro
- Oxlumo
- Rethymic
- Skysona
- Stratagraft
- Tecartus
- Tegsedi
- Viltepso
- Vyondys
- Yescarta
- Zolgensma
- Zynteglo

Cell & Gene Therapy Market Size by Route of Administration

- Injectables
- Infusions
- Bioscaffolds
- Topicals

Cell & Gene Therapy Market Size by Type of Cell

- CAR-T Cell
- TCR Cell

Cell & Gene Therapy Market Size by Type of Therapy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- T-Cell Therapies
- NK Cell
- Dendritic Cell Therapies
- Stem Cell Therapies

Cell & Gene Therapy Market Size by Source of Cell

- Autologous
- Allogenic

Cell & Gene Therapy Market Size by Delivery Mode

- In vivo
- ex-vivo

Cell & Gene Therapy Market Size by Source of Manufacturing

- In-House
- Contract Manufacturing

Cell & Gene Therapy Market Size by Therapeutic Class

- Oncology
- Neurology
- Ophthalmology
- Musculoskeletal
- Others

Cell & Gene Therapy Market Size by Technology

- Viral Vector Technology
- Cell Immortalization Technology
- Genome Editing Technology
- Others

Cell & Gene Therapy Market Size by End User

- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Hospital & Clinics

Cell & Gene Therapy Market Size by Regions

- North America
 - U. S.
 - Canada
 - Mexico
- Europe
 - France
 - United Kingdom
 - Germany
 - Italy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Netherlands

- Asia-Pacific

- China

- Japan

- Australia

- India

- South Korea

- MEA region

- Israel

- South Africa

- U.A. E

- Saudi Arabia

- Latin America

- Brazil

- Argentina

- Colombia

Key Companies Covered

- Gilead Company

- Novartis

- Roche Holding AG

- Johnson & Johnson

- Bristol Myers Squibb

- bluebird bio

- Alnylam Pharmaceuticals

Module 6 Regulatory Outlook

This module contains a detailed understanding of the ethical, legal, and social implications of cell and gene therapy technology.

Table of Contents:

This market intelligence report features an in-depth analysis on the current market dynamics of cell and gene therapy market.

It provides a detailed analysis of cell and gene therapy market dynamics, covering clinical trials, patent data, financial deals, and competitive landscape through 38 sections, 1048 tables, and 1513 charts.

Chapter 1 About this Report

1.1 Research Methodology

1.2 Definitions

1.3 Disclaimer

Chapter 2 Global Cell and Gene Therapy Market Outlook and Future Growth Dynamics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.1 Introduction
- 2.2 Market Opportunities and Growth Dynamics
- 2.3 Strategy and Innovations
- 2.4 Regulation and Challenges Related to Cell and Gene Therapy Around the Globe

Chapter 3 Regulatory Dynamics Assessment Across Different regions

- 3.1 North America Cell and Gene Therapy Regulations
- 3.2 Europe Cell and Gene Therapy Regulations
- 3.3 Asia Pacific Cell and Gene Therapy Regulations
- 3.4 Latin America Cell and Gene Therapy Regulations
- 3.5 Middle East & Africa region Cell and Gene Therapy Regulation

Chapter 4 Global Cell and Gene Therapy Discovery and Clinical Pipeline Market Attractiveness

- 4.1 Cell and Gene Therapy Based: Discovery and Clinical Pipeline, 2023
- 4.2 Cell and Gene Therapy Based: Discovery and Clinical Pipeline, 2024
- 4.3 Cell and Gene Therapy Based: Discovery and Clinical Pipeline, 2025-2027
- 4.4 Approved Cell and Gene Therapies, 2017-2022
- 4.5 Anticipated Regulatory Decisions, 2023
- 4.6 Predicted Cell and Gene Therapy Product Launches, 2018-2030
- 4.7 List of Top 10 Innovation Driving Worldwide CGT Sales in 2022
- 4.8 FDA Approved Cell and Gene Therapies

Chapter 5 Global Cell and Gene Therapy Financial Deals & Alliances Market Dynamics & Outlook

- 5.1 Cell and Gene Therapy Financial Deals & Alliances Market Prediction and Estimation
- 5.2 Cell and Gene Therapy Financial Deals Vs Mergers & Acquisition, 2022 vs 2025
- 5.3 Cell and Gene Therapy Financial Deals Analysis by Different Therapy Segment, 2022 vs 2025
- 5.4 Cell and Gene Therapy Financial Deals Analysis by Type of Cell, 2022 vs 2025
- 5.5 Cell and Gene Therapy Financial Deals Analysis by Therapeutic Class, 2021 vs 2022
- 5.6 Cell and Gene Therapy Financial Deals Analysis by Therapeutic Class Prediction, 2022 vs 2025
- 5.7 Cell and Gene Therapy Financial Deals Analysis by Phase-Wise Deals, 2022 vs 2025
- 5.8 Cell and Gene Therapy Financial Deals Analysis by Type of Diseases, 2022 vs 2025
- 5.9 Cell and Gene Therapy Financial Deals Analysis by Type of Industry, 2022 vs 2025
- 5.10 Cell and Gene Therapy Financial Deals Analysis by Region, 2022 vs 2025
- 5.11 Cell and Gene Therapy Financial Deals Total Upfront Cash and Equity, 2018-2022
- 5.12 Number of Cell and Gene Therapy in Clinical Stage, 2018-2022
- 5.13 Recent Deals and Partnership of Cell and Gene Therapy
- 5.14 Recent Cell and Gene Therapy Mergers and Acquisitions
- 5.15 Global Cell and Gene Therapy Deals Landscape, 2020-2022
- 5.16 Cell and Gene Therapy Financial Deals Analysis by Funding and Investment

Chapter 6 Global Cell and Gene Therapy Patent Analysis & Outlook

- 6.1 Cell and Gene Therapy Historical and Futuristic Trend of Patent, 2018-2027
- 6.2 Cell and Gene Therapy Patent Analysis by Type of Cell Therapy Players, 2022 vs 2025

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3 Cell and Gene Therapy Patent Analysis by Type of Gene Therapy Player, 2022 vs 2025
- 6.4 Cell and Gene Therapy Patent Analysis by Cell Type, 2022 vs 2025
- 6.5 Cell and Gene Therapy Patent Analysis by Product
- 6.6 Cell Therapy Patent Analysis by Patent Type, 2018-2022
- 6.7 Gene Therapy Patent Analysis by Patent Type, 2018-2022
- 6.8 Cell Therapy Patent Analysis by Legal Status, 2018-2022
- 6.9 Gene Therapy Patent Analysis by Legal Status, 2018-2022
- 6.1 Cell Therapy Patent Analysis by Top Patent Owners
- 6.11 Gene Therapy Patent Analysis by Top Patent Owners
- 6.12 Cell Therapy Patent Analysis by Top Patent Applicants
- 6.13 Gene Therapy Patent Analysis by Top Patent Applicants
- 6.14 Cell and Gene Therapy: Cell Therapy Top Patent Applicants Benchmarking Analysis
- 6.15 Cell and Gene Therapy: Gene Therapy Key Patent Applicant Benchmarking Analysis
- 6.16 Cell Therapy Patent Analysis by Published Status
- 6.17 Gene Therapy Patent Analysis by Published Status
- 6.18 Cell Therapy Patent Analysis by Investors
- 6.19 Gene Therapy Patent Analysis by Investors
- 6.20 Cell Patent Analysis by CPC Classification Code
- 6.21 Gene Therapy Patent Analysis by CPC Classification Code
- 6.22 Cell Therapy Patent Documents by Jurisdiction
- 6.23 Gene Therapy Patent Documents by Jurisdiction
- 6.24 List of Recent Cell Therapy Patents
- 6.25 List of Recent Gene Therapy Patents

Chapter 7 Cell and Gene Therapy Clinical Trial Analysis & Outlook

- 7.1 Cell and Gene Therapy Clinical Trial Historical and Futuristic Trend
- 7.2 Cell and Gene Therapy Clinical Trial Region-wise Prediction & Estimation, 2018-2027
- 7.3 Cell Therapy Clinical Trial Analysis by Country-wise Analysis
- 7.4 Gene Therapy Clinical Trial Analysis by Country-wise
- 7.5 Cell and Gene Therapy Clinical Trial Analysis by Age Group
- 7.6 Cell and Gene Therapy Clinical Trial Analysis by Funding Agency
- 7.7 Cell and Gene Therapy Clinical Trial Analysis by Documents
- 7.8 Cell and Gene Therapy Clinical Trial Analysis by Therapeutic Class
- 7.9 Cell and Gene Therapy Clinical Trial Analysis by Phase-wise
- 7.10 Cell and Gene Therapy Clinical Trial Analysis by Status
- 7.11 Number of Cell and Gene Therapy Assets in Clinical Pipeline
- 7.12 Cell and Gene Therapy Clinical Trial Analysis by Type of Diseases
- 7.13 Cell and Gene Therapy Clinical Trial Analysis by Study Type

Chapter 8 Cell and Gene Therapy Competitive Landscape Analysis: Key Company Profiles and Strategic Initiatives

- 8.1 Cell and Gene Therapy Competitive Index Ranking & Attractiveness Quadrant
- 8.2 Cell and Gene Therapy Company Market Share
- 8.3 Cell and Gene Therapy Competitive Mapping Quadrant
- 8.4 Cell and Gene Therapy Competitive Landscape by End Markets
- 8.5 Key Companies by Regions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.6 Competitive Landscape by Different Therapy Segment of Cell and Gene Therapy
- 8.7 Gene Therapy Public Company Competitive Landscape
- 8.8 Cell Therapy Public Company Competitive Landscape
- 8.9 Cell and Gene Therapy Developers Worldwide
- 8.10 Gilead Sciences
- 8.11 Novartis
- 8.12 Johnson & Johnson
- 8.13 Bristol Myers Squibb
- 8.14 Roche Holding AG
- 8.15 bluebird bio
- 8.16 Alnylam Pharmaceuticals

Chapter 9 Global Cell and Gene Therapy Market Size and Forecast, 2018-2027

- 9.1 Cell and Gene Therapy Market Share by Different Therapy Segment, 2018-2027
 - 9.1.1 Market Size by Cell and Gene Modified Cell Therapies, 2018-2027
 - 9.1.2 Market Size by Gene Therapy and Genome Therapy, 2018-2027
 - 9.1.3 Cell and Gene Therapy Market Size by DNA & RNA Therapeutics, 2018-2027
- 9.2 Cell and Gene Therapy Market Share by Purpose of Manufacturing, 2018-2027
 - 9.2.1 Cell and Gene Therapy Market Size by Commercial, 2018-2027
 - 9.2.2 Cell and Gene Therapy Market Size by Clinical, 2018-2027
- 9.3 Cell and Gene Therapy Market Share by Product, 2018-2027
- 9.4 Cell and Gene Therapy Market Share by Route of Administration, 2018-2027
 - 9.4.1 Cell and Gene Therapy Market Size by Injectables, 2018-2027
 - 9.4.2 Cell and Gene Therapy Market Size by Topicals, 2018-2027
 - 9.4.3 Cell and Gene Therapy Market Size by Infusions, 2018-2027
 - 9.4.4 Cell and Gene Therapy Market Size by Bioscaffolds, 2018-2027
- 9.5 Cell and Gene Therapy Market Share by Type of Diseases, 2018-2027
 - 9.5.1 Cell and Gene Therapy Market Size by Rare Diseases, 2018-2027
 - 9.5.2 Cell and Gene Therapy Market Size by Non-Rare Diseases, 2018-2027
- 9.6 Cell and Gene Therapy Market Share by Type of Cell, 2018-2027
 - 9.6.1 Cell and Gene Therapy Market Size by CAR-T Cell, 2018-2027
 - 9.6.2 Cell and Gene Therapy Market Size by TCR Cell, 2018-2027
- 9.7 Cell and Gene Therapy Market Share by Therapy, 2018-2027
 - 9.7.1 Cell and Gene Therapy Market Size by T-Cell Therapies, 2018-2027
 - 9.7.2 Cell and Gene Therapy Market Size by NK Cell, 2018-2027
 - 9.7.3 Cell and Gene Therapy Market Size by Dendritic Cell Therapies, 2018-2027
 - 9.7.4 Cell and Gene Therapy Market Size by Stem Cell Therapies, 2018-2027
- 9.8 Cell and Gene Therapy Market Share by Source of Cell, 2018-2027
 - 9.8.1 Cell and Gene Therapy Market Size by Autologous, 2018-2027

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.8.2 Cell and Gene Therapy Market Size by Allogenic, 2018-2027

9.9 Cell and Gene Therapy Market Share by Delivery Mode, 2018-2027

9.9.1 Cell and Gene Therapy Market Size by In-vivo, 2018-2027

9.9.2 Cell and Gene Therapy Market Size by Ex-vivo, 2018-2027

9.10 Cell and Gene Therapy Market Share by Source of Manufacturing, 2018-2027

9.10.1 Cell and Gene Therapy Market Size by In-House, 2018-2027

9.10.2 Cell and Gene Therapy Market Size by Contract Manufacturing, 2018-2027

9.11 Cell and Gene Therapy Market Share by Therapeutic Class, 2018-2027

9.11.1 Cell and Gene Therapy Market Size by Oncology, 2018-2027

9.11.2 Cell and Gene Therapy Market Size by Neurology, 2018-2027

9.11.3 Cell and Gene Therapy Market Size by Ophthalmology, 2018-2027

9.11.4 Cell and Gene Therapy Market Size by Musculoskeletal, 2018-2027

9.11.5 Cell and Gene Therapy Market Size by Others, 2018-2027

9.12 Cell and Gene Therapy Market Share by Technology, 2018-2027

9.12.1 Cell and Gene Therapy Market Size by Viral Vector Technology, 2018-2027

9.12.2 Cell and Gene Therapy Market Size by Cell Immortalization Technology, 2018-2027

9.12.3 Cell and Gene Therapy Market Size by Genome Editing Technology, 2018-2027

9.12.4 Cell and Gene Therapy Market Size by Others Technologies, 2018-2027

9.13 Cell and Gene Therapy Market Share by End User, 2018-2027

9.13.1 Cell and Gene Therapy Market Size by Pharmaceutical & Biotechnology Companies, 2018-2027

9.13.2 Cell and Gene Therapy Market Size by Academic & Research Institutes, 2018-2027

9.13.3 Cell and Gene Therapy Market Size by Hospital & Clinics, 2018-2027

Chapter 9 - Chapter 38: This section contains chapters providing cell and gene therapy market sizing and forecast for additional 20 countries and 6 regions.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Cell and Gene Therapy Business and Investment Opportunities - Analysis and Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update

Market Report | 2023-02-22 | 1350 pages | BioIntel360

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|-----------------------|------------|
| | Single User Price | \$8900.00 |
| | Multi User Price | \$9900.00 |
| | Enterprise User Price | \$11900.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|---|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | <input type="text" value="2026-03-05"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.